The Hygiology Post ® is presenting information about a company that seems to have much potential to help many people. The years 2012, 2013, and 2014 do appear to likely be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site. As a matter of disclosure : The author continues to be a current shareholder in the company.
An important article identified as being released at 7:15 AM this morning at on the Senesco Technologies web site (https://www.senesco.com/newsitem.php?id=293; obtained on 1-9-14) began the following way:
First Patient in Cohort 4 Receives Infusion of Senesco’s Therapeutic Candidate, SNS01-T, For the Treatment of Multiple Myleoma and Non-Hodgkins Lymphoma in Phase 1b/2a Clinical Trial
BRIDGEWATER, N.J. (January 9th, 2014) – Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (OTC QB: SNTI) reported the administration of SNS01-T to the first patient in cohort 4 of its Phase 1b/2a study in multiple myeloma and non-Hodgkins B-cell lymphoma.
‘We are very pleased that the first patient in cohort 4 has begun receiving SNS01-T. We now have five sites recruiting patients for the clinical trial and expect to increase this number in order to maintain enrollment into the study and meet our goal of completing cohort 4 in the first half of 2014,’ stated Leslie J. Browne, Ph.D., President and CEO of Senesco. ‘The dose level in cohort 4 of 0.375 mg/kg of SNS01-T is the dose that was most efficacious in the non-clinical cancer models that we used. As we have increased the dose level through the first 3 patient groups we have observed a steady increase in SNS01-T’s effect. We expect this trend to continue.’
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2014 The Hygiology Post ®